Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN102,4102,550,39
Msft0,16
Nokia3,1783,19-0,31
IBM-0,82
Daimler AG53,6153,64-0,70
PFE-1,00
14.11.2019 1:38:41
Indexy online
AD Index online
select
AD Index online
 

  • 13.11.2019 21:59:59
Agilent Tech (A, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
77,15 0,13 0,10 907 218
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.11.2019
Popis společnosti
Obecné informace
Název společnostiAgilent Technologies Inc
TickerA
Kmenové akcie:Ordinary Shares
RICA
ISINUS00846U1016
Poslední známé roční výsledky31.10.2018
Poslední známé čtvrtletní výsledky31.07.2019
Počet zaměstnanců k 31.07.2019 15 700
Akcie v oběhu k 23.08.2019 309 467 678
Počet akcionářů k 31.10.2018 22 187
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice5301 Stevens Creek Blvd
MěstoSANTA CLARA
PSČ95051-7201
ZeměUnited States
Kontatní osobaAnkur Dhingra
Funkce kontaktní osobyInvestor Relations
Telefon14 083 458 886
Fax14083458474
Kontatní telefon14 083 458 862

Business Summary: Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Financial Summary: BRIEF: For the nine months ended 31 July 2019, Agilent Technologies Inc revenues increased 5% to $3.8B. Net income before extraordinary items increased 34% to $877M. Revenues reflect Life Sciences and Applied Markets segment increase of 48% to $1.68B, Agilent CrossLab segment increase of 64% to $1.36B, Diagnostics and Genomics segment increase of 69% to $752M. Net income benefited from Agilent CrossLab segment income increase of 20% to $342M.
Odvětvová klasifikace
TRBC2012Advanced Medical Equipment & Technology - NEC
RBSS2004Electrical Components & Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICSAnalytical Laboratory Instrument Manufacturing
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
SICInstruments To Measure Electric
SICAnalytical Instruments
SICElectromedical Equipment



  • Poslední aktualizace: 14.11.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardBoon Hwee Koh6815.03.201715.03.2017
President, Chief Executive Officer, DirectorMichael McMullen5718.03.2015
Chief Financial Officer, Senior Vice PresidentRobert McMahon5001.09.201803.08.2018
Senior Vice President, General Counsel, SecretaryMichael Tang4406.01.201606.01.2016
Senior Vice President - Human ResourcesDominique Grau5901.08.201401.08.2014
Senior Vice President, President - Order FulfillmentHenrik Ancher-Jensen53
Senior Vice President, President - Agilent CrossLab GroupMark Doak63
Senior Vice President, President, Diagnostics and Genomics GroupSamraat Raha46
Senior Vice President, President, Life Sciences and Applied Markets GroupJacob Thaysen4324.04.2018
Chief Accounting Officer, Vice President, Corporate ControllershipRodney Gonsalves5307.05.201507.05.2015